Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients

Objectives: Monoclonal antibodies (mAbs) have proven to be a valuable tool against COVID-19, mostly among subjects with risk factors for progression to severe illness. Tixagevimab/cilgavimab (TIX/CIL), a combination of two Fc-modified human monoclonal antibodies, has been recently approved to be emp...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardi, Andrea, Viero, Giulia, Villa, Simone, Biscarini, Simona, Palomba, Emanuele, Azzarà, Cecilia, Iannotti, Nathalie, Mariani, Bianca, Genovese, Camilla, Tomasello, Mara, Tonizzo, Anna, Fava, Marco, Valzano, Antonia Grazia, Morlacchi, Letizia Corinna, Donato, Maria Francesca, Castellano, Giuseppe, Cassin, Ramona, Carrabba, Maria, Muscatello, Antonio, Gori, Andrea, Bandera, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295521/
https://www.ncbi.nlm.nih.gov/pubmed/37371635
http://dx.doi.org/10.3390/biomedicines11061540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295521/
https://www.ncbi.nlm.nih.gov/pubmed/37371635
http://dx.doi.org/10.3390/biomedicines11061540

Ejemplares similares